

Research 2004-2006

Theresa A. Zesiewicz, MD FAAN
Parkinson's Disease and Movement
Disorders Center
USF

1. Essential Tremor

- Most common adult movement disorder in the world
- 1. Zesiewicz TA, Elble R, Louis ED, Sullivan KL, Hauser RA, Dewey RB Jr, Ondo WG, Gronseth GS, Weiner WJ. Practice Guideline: Treatment of Essential Tremor. Report by the American Academy of Neurology. Neurology 2005

Essential Tremor Research

- Double-blind controlled trials to assess pharmacotherapy for Essential Tremor
- 1. **Zesiewicz TA**, Ward CL, Staffetti JF, Dunne PB, Sullivan KL. A double-blind, placebo-controlled trial of Zonisamide (Zonegran) in the treatment of essential tremor. 58th American Academy of Neurology April 1-8, 2006, San Diego, California. Presented on Wednesday, April 5, S33:004.
- Pregabalin (Lyrica) in the treatment of ET (submitted to Movement Disorders)

2. Parkinson's disease: non-motor symptoms

1. Sullivan KL, Ward CL, Hauser RA, Dunne PB, Zesiewicz TA. Prevalence and treatment of non-motor symptoms in Parkinson's disease. 58th American Academy of Neurology Annual meeting, April 1-8, 2006, San Diego, California. Presented on Wednesday, April 5th, Poster Session P04:031.
2. Lead author on AAN guideline on prevalence, diagnosis, and treatment of non-motor symptoms in PD

Non-motor symptoms: future research

- Performing controlled trials to assess management of non-motor symptoms in PD patients for
 - Urinary incontinence
 - Constipation
 - Anxiety
 - Restless leg syndrome
 - Depression

3. The Role of Antiepileptics in Movement Disorders

- Levetiracetam as an anti-dyskinetic agent
- Zonisamide as an anti-tremor agent
- Pregabalin as an anti-tremor agent
- Evaluation of movement disorder exacerbation with some antiepileptics (i.e., lamictal)

4. Homocysteine

1. Zesiewicz TA, Guinta B, Hauser RA, Hoffman M, Wallach P, Sullivan KL. Levodopa-Induced Hyperhomocysteinemia and Cardiovascular Dysfunction in Parkinsons Disease. MDS Congress, June 15, 2004, at the Palazzo dei Congressi, Rome, Italy, P599.

Homocysteine

1. **Zesiewicz TA, Wecker L**, Sullivan KL, Merlin LR, **Hauser RA**. The Controversy Concerning Plasma Homocysteine in Parkinson's Disease Patients Treated with Levodopa alone or with Entacapone: Effects of Vitamin Status. Clinical Neuropharmacol 2006, (Accepted) In Press.

Future research

- The role of homocysteine in the pathogenesis of additional movement disorders

Papers accepted 2004

- **Zesiewicz TA**, Carter SN, Sullivan KL, Staffetti JF, Dunne PB, Hauser RA. Initial Management of Parkinson's Disease in a Florida Community. *The Journal of Applied Research* 2004;4:95-98.
- Sullivan KL, Hauser RA, **Zesiewicz TA**. Essential Tremor: A Review. *Neurologist*. 2004 Sep;10(5):250-8.
- **Zesiewicz TA**, Strom JA, Borenstein AR, Hauser RA, Cimino CR, Fontanet H, Cintron C, Staffetti JF, Dunne PB, Sullivan KL. Heart Failure in Parkinson's Disease: Analysis of the United States Medicare Current Beneficiary Survey, 1997-1999. *Parkinsonism & Related Disorders* 2004;10:417-420.

Papers accepted 2004

- **Zesiewicz TA**, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial Improvement in a Meige's Syndrome Patient with Levetiracetam Treatment. *Mov Disord* 2004;19:1518-1521.
- **Zesiewicz TA**, Stamey W, Sullivan KL, Hauser RA. Botulinum Toxin A for the Treatment of Cervical Dystonia. *Expert Opin Pharmacother*. 2004 Sep;5(9):2017-24.
- Parkinson Study Group. Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. *N Engl J Med* 2004; In Press (Ms No. 03-3447).

Papers accepted 2005

- Recio MV, Hauser RA, Louis ED, Radhashakar H, Sullivan KL, **Zesiewicz TA**. Chorea in a patient with cerebral palsy: treatment with levetiracetam. *Mov Disord* 2005; 20(6):762-4.
- Sullivan KL, Hauser RA, **Zesiewicz TA**. Levetiracetam in the Treatment of Essential Tremor. *Mov Disorders* 2005;20(5):640.
- **Zesiewicz TA**, Sullivan KL, Maldonado JL, Tatum WO, Hauser RA. Levetiracetam (Keppra) for the Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease. *Mov Disord* 2005, July 13th.

Papers accepted 2005

- **Zesiewicz TA**, Elble R, Louis ED, Sullivan KL, Hauser RA, Dewey RB Jr, Ondo WG, Gronseth GS, Weiner WJ. Practice Guideline: Treatment of Essential Tremor. Report by the American Academy of Neurology. *Neurology* 2005;July 2.
- **Zesiewicz TA**, Sanchez-Ramos J, Sullivan KL, Hauser RH. Levetiracetam-Induced Parkinsonism in a Huntington's Disease Patient. *Clin Neuropharmacol.* 2005;28(4):188-190

Papers accepted 2005

- Sullivan KL, Hauser RA, Louis ED, Chari G, **Zesiewicz TA**. Case Report: Levetiracetam for the Treatment of Generalized Dystonia. *Parkinsonism and Related Disorders* 2005, July 11.
- Sullivan KL, Staffetti JF, Hauser RA, Dunne PB, **Zesiewicz TA**. Tegaserod (Zelnorm) for the Treatment of Constipation in Parkinson's Disease. *Mov Disord* 2006 Jan;21(1):115-6. In Press.

Papers accepted 2005

- **Zesiewicz TA**, Sullivan KL, Hauser RA. Vascular hemichorea/hemiballismus and topiramate. *Mov Disord*. 2005 Dec 8;
- **Zesiewicz TA**, Pathak A, Sullivan KL, Shamayev M, Hauser RA. Treatment of chorea with levetiracetam. *Eur J Clin Pharmacol* 2006 Jan;62(1):87. Epub 2005 Dec 1. In Press.
- Wolfrath SC, Borenstein AR, Schwartz S, Hauser RA, Sullivan KL, **Zesiewicz TA**. Use of Nutritional Supplements in Parkinson's Disease Patients. *Mov Disord* 2005 (Accepted), In Press.

Papers accepted 2006

- **Zesiewicz TA, Sullivan KL. Chorea induced by Lamotrigine therapy. Journal of Child Neurology November 2005 (Accepted), In Press.**
- **Suchowersky O, Perlmutter J, Gronseth G, Reich S, Zesiewicz TA, Weiner WJ. Practice Guideline: Neuroprotective Therapies in Parkinson's Disease. Neurology 2006 (Accepted), In Press.**

Papers accepted 2006

- **Suchowersky O, Reich S, Perlmutter J, Zesiewicz TA, Gronseth G, and Weiner WJ. Practice Parameter: Diagnosis and Prognosis of New Onset Parkinson Disease (An Evidence-Based Review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 (Accepted), In Press.**
- **Zesiewicz TA, Wecker L, Sullivan KL, Merlin LR, Hauser RA. The Controversy Concerning Plasma Homocysteine in Parkinson's Disease Patients Treated with Levodopa alone or with Entacapone: Effects of Vitamin Status. Clinical Neuropharmacol 2006, (Accepted) In Press.**

Papers accepted 2006

- **Zesiewicz TA**, Tullidge A, Tidwell J, Sullivan KL, Hauser RA. Topiramate-Induced Psychosis in Essential Tremor Patients: Report of 2 Cases. Accepted to Clin Neuropharmacol, March 2006.
- **Zesiewicz TA**, Sullivan KL, Hauser RA, Sanchez-Ramos J. An Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington's Disease. Accepted to Mov Disord March, 2006.

Papers accepted 2006

- Hauser RA, **Zesiewicz TA**. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. *Neurology*. 2006 May 23;66(10 Suppl 4):S58-68.
- Sullivan KL, Ward CL, **Zesiewicz TA**. Zonisamide-Induced Mania in an Essential Tremor Patient. *J Clin Psychopharmacol*. 2006 Aug;26(4):439-40.
- **Zesiewicz TA**, Hauser RA. Treatment of Parkinson's Disease. *Continuum*, Fall 2006.